Preferred Label : Insulin Degludec;
NCIt synonyms : (1A-21A),(1B-29B)-Insulin (human), 29B-(N6-(N-(15-carboxy-1-oxopentadecyl)-L-gamma-glutamyl)-L-lysine)-;
NCIt definition : A recombinant, long-acting analog of human insulin, with blood glucose-lowering activity.
Upon subcutaneous injection, insulin degludec forms a multi-hexameric depot from which
insulin monomers are slowly released into the systemic circulation. Insulin regulates
glucose metabolism by binding to insulin receptors on muscle and fat cells, which
stimulates the cellular uptake of glucose and lowers blood glucose levels. Insulin
inhibits the liver's conversion of stored glycogen into glucose, which also contributes
to lower blood glucose levels. In addition, insulin inhibits lipolysis in adipose
tissue, inhibits proteolysis, and enhances protein synthesis. Insulin degludec doesn't
contain the amino acid threonine that is found at position B30 in human insulin; additionally,
the lysine at position B29 is conjugated to hexadecanedioic acid, which allows the
formation of the multi-hexamers upon subcutaneous injection. The phenol and zinc present
in the pharmaceutical formulation promote a di-hexameric state of insulin degludec.;
UNII : 54Q18076QB;
CAS number : 844439-96-9;
Drug name : Tresiba;
Molecule name : NN1250;
Origin ID : C142979;
UMLS CUI : C3491971;
Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
